AtriCure, Inc. $ATRC Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 74.0% in the first quarter, HoldingsChannel.com reports. The firm owned 9,627 shares of the medical device company’s stock after selling 27,454 shares during the quarter. SG Americas Securities LLC’s holdings in AtriCure were worth $275,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ATRC. Marshall Wace LLP lifted its position in shares of AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after buying an additional 354,281 shares during the last quarter. Wellington Management Group LLP grew its position in shares of AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after buying an additional 322,818 shares during the last quarter. First Light Asset Management LLC raised its stake in AtriCure by 32.0% during the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after acquiring an additional 285,083 shares in the last quarter. Kennedy Capital Management LLC raised its stake in AtriCure by 36.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 836,916 shares of the medical device company’s stock worth $29,501,000 after acquiring an additional 222,529 shares in the last quarter. Finally, Norges Bank purchased a new stake in AtriCure in the fourth quarter valued at $8,466,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00. Following the transaction, the director owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the subject of several research analyst reports. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings downgraded AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Canaccord Genuity Group upped their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $48.71.

AtriCure Trading Down 0.8%

Shares of AtriCure stock opened at $34.28 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. The company has a market capitalization of $1.74 billion, a P/E ratio of -342.80 and a beta of 1.24. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $43.18. The company’s fifty day moving average is $28.66 and its two-hundred day moving average is $31.82.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.